Filing Details

Accession Number:
0001209191-23-002412
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-06 17:21:01
Reporting Period:
2022-07-01
Accepted Time:
2023-01-06 17:21:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA In Vitro & In Vivo Diagnostic Substances (2835) 364785571
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1914448 Eliana Clark C/O Intellia Therapeutics, Inc.
40 Erie Street
Cambridge MA 02139
Evp, Chief Technical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-07-01 105 $51.74 16,165 No 4 S Direct
Common Stock Disposition 2023-01-03 231 $34.48 16,165 No 4 S Direct
Common Stock Disposition 2023-01-04 1,692 $37.21 14,473 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Sale of 105 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022.
  2. Sale of 231 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2022.
  3. Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.